Has anyone seen if HLN repurchased some more of its stock as part of the final GSK sell down this week please? |
Money moving to APH ( alliance Pharma ) |
GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 May 2024, GSK has agreed to sell 385,320,110 ordinary shares in Haleon plc ("Haleon") at a price of 324 pence per share (the "Placing Shares"), raising gross proceeds of approximately £1,248m (the "Placing").
Following settlement of the Placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon. |
Good to see Glaxo exiting in an orderly manner. |
Barclays raise HLN target to 400p (383p) - Overweight |
HSBC starts Haleon with 'buy' - price target 370 pence |
Sp showing good strength here in a period when it could well have gone the other way. Next test will probably come when the lock up periods arising from the recent placements finish. |
It is positive that the offer was upsized (ghastly word) by 160m shares one assumes due to institutional demand. |
Not forgetting that a takeover is made easier if a large holder agrees to sell in advance to an acquirer. HLN IMO will get acquired at some point. |
Agree on the divi, not good, GSK still have a rump holding too to offload so more of the same to come from them. I had only kept these post the demerger on the hope that they would be taken over, but guessing that is unlikely or way out in the future once both Pfizer and GSK have done selling... until they are both clear I think the share price will languish in in the current trading range. |
Pfizer to cut stake in HLN - see above. |
Final divi 4.2p
xd 14 March, pd 16 May
Total for year 6.0p
Trailing yield at 330p 1.8% which is low but I'm retaining the shares, received from the GSK demerger, as an income investor. |
Good figures. Debt coming down nicely. |
But reduces debt which is other side of the coin - and probably the shinier side |
Problem with disposals is that they're a short term sticking plaster losing a long term income stream. |
Bon voyage Chapstick, looks like a good deal, cash, pay down debt and a passive forward interest. Let's hope we see an uptick in the share price, we need it! |
Another very welcome placing by GSK, which has now sold down two thirds of the shares it originally held post IPO. Given the cash HLN is throwing off and reports that it might sell one of its brands for up to USD800m I wonder if the company might bid GSK for some or all of its remaining stock later this year. |
GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc ("Haleon") at a price of 326 pence per share (the "Placing Shares"), raising gross proceeds of approximately GBP978m (the "Placing").
Following settlement of the Placing, GSK will hold approximately 385m ordinary shares in Haleon, representing approximately 4.2% of the issued share capital of Haleon. |
Decent director purchase. |
Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.
Still very low though.
I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely! |
Still don't understand what is holding up this share price P/e close to 20 and a yield below 1% makes little sense for this sector.
I expect the company to be taken out but at what price?
Patient, you have holdings here. Do you have any answers; it just seems unsupportable? |
 Haleon seen growing after wobbly start -- Market TalkSource: MF Dow Jones (English)Original article published on Dow Jones English Newswire, translated by editorial staff Il Sole 24 Ore Radiocor.(Il Sole 24 Ore Radiocor Plus) - Milan, Dec 11 - Haleon is expected to start seeing a smoother growth path after facing several challenges since its IPO, Jefferies analysts write in a note after updating their rating on the stock to buy from hold.The 2025 results of the consumer-healthcare sector should at least be in line with expectations, thanks to better and less volatile sales growth, according to Jefferies analysts.Haleon's strategy - which has not yet been employed due to pandemic disruptions and soaring production factor costs - appears to be rekindling with the group's increased engagement in new combined category exposures, they add."Haleon is our favourite name in the consumer health industry, with more predictable and consistent results in both revenue and earnings," they add.Shares are up 0.5% to 326.3 pence.(michael.susin@wsj.com)(END) Dow Jones NewswiresDecember 11, 2023 03:50 AM ET (08:50 GMT)Copyright (c) 2023 Dow Jones-Radiocour |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
